Palvella Therapeutics
Company Details
Status: Private
Employees: 11-50
Location:
Wayne, Pennsylvania, United States
Type:
sample
Technology:
sample
sample
About: Palvella Therapeutics (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a broad pipeline of product candidates based on its patented QTORIN™ platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin), is currently in clinical development for microcystic lymphatic malformations (microcystic LMs) and cutaneous venous malformations. For more information, please go to www.palvellatx.com.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Palvella Therapeutics | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.